2. Search Result
Search Result
Results for "

Th1 immune responses

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

2

Biochemical Assay Reagents

4

Natural
Products

2

Isotope-Labeled Compounds

2

Click Chemistry

8

Oligonucleotides

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-153808
    Complete Freund's adjuvant (CFA)
    Maximum Cited Publications
    15 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
    Complete Freund's adjuvant (CFA)
  • HY-146244
    Agatolimod
    1 Publications Verification

    ODN 2006; PF-3512676; CpG 7909; ODN 7909

    		 Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis Infection Cancer
    Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
    Agatolimod
  • HY-101092
    QS-21-Api
    5+ Cited Publications

    Stimulon

    		 NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    QS-21-Api, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21-Api stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21-Api can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18 .
    QS-21-Api
  • HY-150724
    ODN 1018
    2 Publications Verification

    1018 ISS

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
    ODN 1018
  • HY-153808B
    Complete Freund's adjuvant (CFA, 1 mg/ml)

    		Toll-like Receptor (TLR) Inflammation/Immunology
    Complete Freund's adjuvant (CFA, 1 mg/ml) is an immunoadjuvant emulsified with antigen that can enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA, 1 mg/ml) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA, 1 mg/ml) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA, 1 mg/ml) stimulates a strong and durable immune response and can be used to induce rheumatoid arthritis in rats, and more .
    Complete Freund's adjuvant (CFA, 1 mg/ml)
  • HY-137131
    DC-Chol hydrochloride

    DC-Cholesterol hydrochloride

    		 Amyloid-β Liposome IFNAR Interleukin Related Neurological Disease Inflammation/Immunology
    DC-Chol hydrochloride is a cationic lipid. DC-Chol hydrochloride could inhibit Aβ40 fibril formation under appropriate experimental conditions. DC-Chol hydrochloride strongly inhibits amyloidogenesis of oxidized hCT in a dose-dependent manner. DC-Chol hydrochloride induces the production of Th1 (IL-2 and IFN-γ) and Th2 (IL-5) cytokines. DC-Chol hydrochloride can enhance the body's immune response to antigens. DC-Chol hydrochloride is used as a gene delivery vector. DC-Chol hydrochloride can be used in research in areas such as hepatitis B vaccines to improve vaccine immunity .
    DC-Chol hydrochloride
  • HY-112137
    Trehalose-6,6'-dibehenate

    		Caspase Interleukin Related MyD88 Inflammation/Immunology
    Trehalose-6,6'-dibehenate is an orally active glycolipid. Trehalose-6,6'-dibehenate activates Mincle and inflammasome, inducing IL-1β secretion in a caspase activity-dependent manner. Trehalose-6,6'-dibehenate exerts a Myd88-dependent adjuvant activity. Trehalose-6,6'-dibehenate induces Th-1/Th-17 immune responses .
    Trehalose-6,6'-dibehenate
  • HY-150217
    CpG ODN 10101
    2 Publications Verification

    ODN 10101

    		 Toll-like Receptor (TLR) Infection Inflammation/Immunology
    CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .
    CpG ODN 10101
  • HY-101092B
    QS-21-Xyl

    		Drug Intermediate Inflammation/Immunology Cancer
    QS-21-Xyl is a active component of QS-21 (HY-101092A). QS-21 is a natural vaccine adjuvant and induces a balanced Th1/Th2 immune response, particularly cellular immunity .
    QS-21-Xyl
  • HY-164485
    INI-4001

    		Toll-like Receptor (TLR) SARS-CoV Infection
    INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)3 and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)3, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19 .
    INI-4001
  • HY-N0885
    Telocinobufagin
    1 Publications Verification

    Telobufotoxin; Telocinobufogenin

    		 JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na +/K +-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .
    Telocinobufagin
  • HY-159102
    PVP-037.2

    		Toll-like Receptor (TLR) Inflammation/Immunology
    PVP-037.2 is a TLR7/8 agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced TH1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c .
    PVP-037.2
  • HY-142998
    Vaxfectin

    		Liposome Interleukin Related IFNAR Infection Inflammation/Immunology
    Vaxfectin is a second-generation cationic lipid-based suspension that adjuvants effectively both pDNA and protein-based vaccines. Vaxfectin can boost the immune response against a range of pDNA-expressed pathogenic antigens in vivo. Vaxfectin can increase IgG titers and give rise to an IL-6 dependent enhancement of the humoral immune response without altering the Th1 type immune response. Vaxfectin can be studied for vaccine formulation .
    Vaxfectin
  • HY-158694A
    TLR7 agonist 20 hydrochloride

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 20 hydrochloride is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 0.22 μM. TLR7 agonist 20 hydrochloride, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 hydrochloride can be used in studies related to non-inflammatory potent vaccine adjuvants .
    TLR7 agonist 20 hydrochloride
  • HY-N15846
    VSA 1

    		Drug Derivative Infection Inflammation/Immunology
    VSA 1, a semisynthetic QS-21 (HY-101092) analog, is a saponin adjuvant. VSA 1 potentiates antigen-specific IgG1 and IgG2a immune responses in BALB/c mice, indicating a mixed Th1/Th2 immune response. VSA 1 significantly improves vaccine efficacy after primary immunization and enhances homologous protection .
    VSA 1
  • HY-178240
    rel-(1S,2R)-Dihydro bupropion

    		Interleukin Related Endogenous Metabolite TNF Receptor Inflammation/Immunology
    rel-(1S,2R)-Dihydro bupropion is a metabolite of bupropion. rel-(1S,2R)-Dihydro bupropion can promote endogenous IL-10 production and inhibit Th1 cytokines (IL-12 and TNF-α). rel-(1S,2R)-Dihydro bupropion can induce immune response transition from Th1 to Th2. rel-(1S,2R)-Dihydro bupropion can be used for research on inflammatory conditions .
    rel-(1S,2R)-Dihydro bupropion
  • HY-158694
    TLR7 agonist 20

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 20 is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 0.22 μM. TLR7 agonist 20, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 can be used in studies related to non-inflammatory potent vaccine adjuvants .
    TLR7 agonist 20
  • HY-164454
    AJI-100

    		Aurora Kinase STAT JAK Mitosis Inflammation/Immunology
    AJI-100 is a dual-target inhibitor of Aurora kinase A and JAK2 with IC50 values of 12.7 nM and 18.5 nM, respectively. AJI-100 directly blocks Aurora kinase A to inhibit T cell mitosis and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-100 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .
    AJI-100
  • HY-163704
    KRN7000 analog 1

    		IFNAR Interleukin Related Inflammation/Immunology Cancer
    KRN7000 analog 1 exhibits good Th1-biased immune response through induction of interferon-γ (IFN-γ) and reduction of interleukin-4 (IL-4). KRN7000 analog 1 is potential as an antitumor agent and vaccine adjuvant .
    KRN7000 analog 1
  • HY-159754
    HS201

    		Toll-like Receptor (TLR) Inflammation/Immunology
    HS201 is a nucleotide extract that can be used as a vaccine adjuvant. HS201 can activate Toll-like receptors and trigger Th1 immune responses. HS201 is mainly used in inactivated vaccines for diseases such as foot-and-mouth disease.
    HS201
  • HY-164455
    AJI-214

    		STAT JAK Aurora Kinase Mitosis Inflammation/Immunology
    AJI-214 is a dual-target inhibitor of Aurora kinase A and JAK2. AJI-214 directly blocks Aurora kinase A to inhibit T cell mitotic progression and cell polarity, and inhibits JAK2 activation to inhibit STAT3 phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-214 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .
    AJI-214
  • HY-W777138
    rel-(1S,2R)-Dihydro bupropion-d9

    		Isotope-Labeled Compounds Endogenous Metabolite TNF Receptor Interleukin Related Inflammation/Immunology
    rel-(1S,2R)-Dihydro bupropion-d9 is the deuterium labeled rel-(1S,2R)-Dihydro bupropion (HY-178240). rel-(1S,2R)-Dihydro bupropion is a metabolite of bupropion. rel-(1S,2R)-Dihydro bupropion can promote endogenous IL-10 production and inhibit Th1 cytokines (IL-12 and TNF-α). rel-(1S,2R)-Dihydro bupropion can induce immune response transition from Th1 to Th2. rel-(1S,2R)-Dihydro bupropion can be used for research on inflammatory conditions .
    rel-(1S,2R)-Dihydro bupropion-d9
  • HY-W745349
    rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride

    		Isotope-Labeled Compounds Endogenous Metabolite TNF Receptor Interleukin Related Inflammation/Immunology
    rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride is the deuterium labeled rel-(1S,2R)-Dihydro bupropion hydrochloride (HY-178240). rel-(1S,2R)-Dihydro bupropion is a metabolite of bupropion. rel-(1S,2R)-Dihydro bupropion can promote endogenous IL-10 production and inhibit Th1 cytokines (IL-12 and TNF-α). rel-(1S,2R)-Dihydro bupropion can induce immune response transition from Th1 to Th2. rel-(1S,2R)-Dihydro bupropion can be used for research on inflammatory conditions .
    rel-(1S,2R)-Dihydro bupropion-d9 hydrochloride
  • HY-181740
    GCB-27b

    		CD1 Cancer
    GCB-27b is an immunostimulant that binds to CD1d. GCB-27b forms a stable and long-lasting complex with CD1d, which is presented to the TCR of NKT cells to drive immune responses. GCB-27b induces a Th1-skewed immune response in *Mus musculus*, resulting in high expression of IFN?γ with restricted IL-4 levels. GCB-27b is applicable to research related to lung metastasis of melanoma .
    GCB-27b
  • HY-181739
    GCB-27a

    		CD1 Cancer
    GCB-27a is a CD1d-binding immunostimulant and antitumor agent. GCB-27a binds to CD1d to form a stable complex and presents it to NKT cells, enhancing hydrophobic interactions within the A' pocket of CD1d through branched-chain conformation restriction. GCB-27a induces a Th1-biased immune response, drives IFN?γ production and limits IL-4 levels. GCB-27a is applicable to research related to melanoma lung metastasis .
    GCB-27a

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: